{{Rsnum
|rsid=17099545
|Gene=LOC100128088
|Chromosome=11
|position=102761462
|Orientation=plus
|GMAF=0.07851
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 100.0 | 0.0 | 0.0
| HCB | 65.7 | 29.9 | 4.4
| JPT | 72.6 | 25.7 | 1.8
| YRI | 79.6 | 19.7 | 0.7
| ASW | 77.2 | 21.1 | 1.8
| CHB | 65.7 | 29.9 | 4.4
| CHD | 69.7 | 29.4 | 0.9
| GIH | 88.1 | 10.9 | 1.0
| LWK | 86.4 | 13.6 | 0.0
| MEX | 79.3 | 19.0 | 1.7
| MKK | 96.8 | 3.2 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs17099545
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.03, combined P value= 5.36E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470244
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17099545
|overall_frequency_n=9
|overall_frequency_d=128
|overall_frequency=0.0703125
|n_genomes=7
|n_genomes_annotated=0
|n_haplomes=7
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}